CA1256034A - Antiperspirant compositions containing certain antihistamines and certain antihistamine enhancers - Google Patents
Antiperspirant compositions containing certain antihistamines and certain antihistamine enhancersInfo
- Publication number
- CA1256034A CA1256034A CA000457159A CA457159A CA1256034A CA 1256034 A CA1256034 A CA 1256034A CA 000457159 A CA000457159 A CA 000457159A CA 457159 A CA457159 A CA 457159A CA 1256034 A CA1256034 A CA 1256034A
- Authority
- CA
- Canada
- Prior art keywords
- antihistamine
- composition
- antiperspirant
- enhancer
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Abstract
ABSTRACT OF THE DISCLOSURE
A topical antiperspirant composition containing an antihistamine selected from the group consisting of antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their corresponding pharmaceutically acceptable salts and an enhancer for said antihistamine selected from the group consisting of sodium sulfate, glutamic acid; octyl palmitate and propylene glycol methyl ether.
A topical antiperspirant composition containing an antihistamine selected from the group consisting of antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their corresponding pharmaceutically acceptable salts and an enhancer for said antihistamine selected from the group consisting of sodium sulfate, glutamic acid; octyl palmitate and propylene glycol methyl ether.
Description
3.25~034 ANTIPERSPIRANT COMPOSITIONS CONTCERTAIN ANTIHISTAMINES AND CERTAIN ANTIHISTAMINE ENHANCERS , ,,, _ .
This invention relates to topical antiperspirant compositions that make use of certain antihistamines. More particularly, it concerns compositions of this character that contain an enhancer for the antiperspirant activity of said antihistamines.
It has been suggested in the prior art to use certain antihistamines, alone or in combination with astringent metallic salts, as antiperspirant agents. This is exemplified by two U.S. Patents to Packman et al 4,226,850 and 4,234,566.
In addition, in an article by Goodall published in the J.
Clin. Pharm., Vol. 10, 1970, p. 235-246, it is suggested that certain anticholenergic or cholenergic blocking agents exhibit varying degrees of antiperspirant activity. Among the drugs that Goodall characterizes as anticholenergic drugs, he includes chlorpheniramine maleate, phenindamine tartrate, diphenhydramine HCl and tripelennamine HCl.
A somewhat similar disclosure is to be found in "Advances in Modern Toxicology", Vol. 4, Dermatology and Pharmacology, Chapter 1, pages 2-15, edited by Francis N. Marzuli and Howard I. Maibach, published 1977, John Wiley & Sons, New York.
One thing that is quite clear from this prior art is that the vehicle from which these drugs are applied is important. The level of antiperspirant activity that these drugs exhibit is very much dependent upon the contents of the vehicle in which they are dispensed.
It has now been found that the antiperspirant activity of certain antihistamines may be enhanced by incorporating in a vehicle containing said antihistamine, an enhancer for said antihistamine described in more detail below.
~ V~4 It is accordingly an object of an aspect of the present invention to provide an antiperspirant composition contain-ing certain antihistamines as an active antiperspirant agent and also containing certain agents that enhance the anti-perspirant activity of said antihistamines.
It is an object of an aspect of this invention to provide a process for inhibiting perspiration in a subject that makes use of the antiperspirant composition of the aforesaid object.
Other and more detailed objects of this invention will - be apparent from the following description and claims.
An aspect of this invention is as follows:
A topical antiperspirant composition comprising an active antiperspirant agent consisting essentially of an antihistamine distributed in a vehicle containing an enhancer for the antiperspirant activity of said antihistamine (a) said antihistamine being selected from the group consisting of antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their corresponding pharmaceutically acceptable salts;
(b) said antihistamine enhancer being selected from the group consisting of sodium sulfate, glutamic acid, octyl palmitate and propylene glycol methyl ether;
(c) said antihistamine being present in said vehicle in sufficient concentration to inhibit perspiration; and (d) said enhancer also being present in said vehicle at a concentration sufficient to enhance the antiperspirant effectiveness of said antihistamine.
In the practice of the present invention, it has been found that it is necessary to be quite selective in the antihistamine that is employed. For the purposes of this invention, a composition is an effective antiperspirant composition if it could be demonstrated to be at least weakly effective in the Rat Foot Pad Model described in ~25603~
-2a-more detail below without regard as to whether these results could be corroborated in clinical studies in human antiper-spirant panels. The antihistamines that were found to be effective in accordance with the present invention are antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their pharmaceutically acceptable salts.
The type of salts of the aforesaid antihistamines that are useful for the purposes of this invention can vary. By way of example, the following may be mentioned: phosphates, maleates, hydrochlorides, succinates and tartrates.
The quantity of antihistamine that may be contained in the present compositions may vary somewhat depending on the vehicle utilized and the results that are desired.
However, generally, this will be in the range of from about lS 1% to about 10~ by weight based on the total weight of the ~25~34 composition; the preferred range being from about 3% to about 5% on the same weight basis.
As previously indicated, it is a feature of the present invention to incorporate in the instant antiper-spirant compositions certain enhancers for the antiperspirantactivity of the antihistamines employed. These also are quite selective and include sodium sulfate, glutamic acid (e.g. ~-glutamic acid) octyl palmitate and propylene glycol methyl ether. The quantity of the antihistamine enhancers that will be present in these compositions may also vary somewhat. Usually, this will constitute between about 5% to about 95% by weight based on the total weight of the composition. Best results are obtained when the antiperspirant enhancer utilized falls within the range of from about 5% to about 30% by weight based on the total weight of the composition.
In accordance with the present invention, the anti-histamine and the antihistamine enhancer will be distributed in a suitable vehicle which will generally be a liquid or fluid carrier. This will include solutions, suspensions, lotions, creams, ointments and the like. A variety of carriers may be employed but usually this will be an aqueous based carrier. By way of example, the following carriers may be mentioned: water, propylene glycol, ethanol, ~olatile silicones, ethoxylated ethers, isopropyl myristate and palmitate, etc.
In addition to the components mentioned above, the compositions of this invention may also contain those well known ingredients or adjuvants commonly found in antiperspirant compositions. These include such things as perfumes, coloring agents, stabilizers, buffers, thickeners, emulsifiers, etc.
~2S6034 The compositions of the present invention may be applied to a subject in the conventional manner to inhibit perspiration. Usually, this will involve applying to axillary vault of the subject a quantity of the composition sufficient to inhibit perspiration. This may vary depending upon the results desired, the concentration of the active ingredients and the vehicle employed. Generally, enough of the composition will be applied to dellver to the site from about 10 mgs to about 15 mgs of antihistamine per axilla.
The following Examples are given to further illustrate this invention. It is to be understood, however, that the invention is not limited thereto.
There is given in tabular form in Table I below Examples of the following invention in which the vehicle is primarily water in which the antihistamine and enhancer are dissolved.
--~25~034 TABLE I
~ by Weight based on total wt. of composition Ex Ex Ex Ex Ex ExEx Ex Antihistamine (1) Antazoline phosphate 5 -- -- -- -- -- -- --( 2 ) Pyri lamine maleate -- 5 -- -- -- -- 5 --(3) Tripelennamine hydrochloride -- -- 5 -- -- ~~ ~~ ~~
(4) Diphenhydramine hydrochloride -- -- -- 5 -- -- -- 5 (5) Phenindamine tartrate -- -- -- -- 5 5 -- --Enhancers (6) Sodium sulfate 20 20 20 20 20 -- -- --(7) Q-glutamic acid -- -- -- -- -- 20-- --*
(8) DOWANOL PM -- -- -- -- -- --15 --~ **
(9) CERAPHYL 368 -- -- -- -- -- -- -- 95 Vehicle (10) Water QS 100 100 100 100 100 100 100 --* Propylene glycol methyl ether ** Octyl palmitate As indicated previously, the antiperspirant effectiveness of the compositions of the present invention were evaluated using the Rat Foot Pad Model. This procedure is discussed below.
~,~, 125~34 Rat Foot Pad Model Materials and Methods Female rats were utilized since they sweated more consistently than the male rats. Each material was evaluated in six Sprague Dawley rats (Taconic Farms, weight range 175-250 gm).
Three animals were injected (i.m.) in the right hind limb and three in the left hind limb (biceps femoris area) with 0.02 ml of Innovar Vet. This dose sedated the rats and facilitated placing them into polyethylene harnesses which were then fastened around each animal using binder clips.
The harnessed rats were attached horizontally to supportiny rods by wire hooks. In this manner, they were prevented from walking or licking their feet during the test.
Prior to treatment, the foot pads of both hind feet were swabbed with 70% alcohol to remove cellular debris.
Treatment consisted of immersing the right hind foot into the test material for one minutê. The foot was then allowed to air dry. The left hind foot served as an untreated control.
Observation of Sweat Inhibition/Rating One hour post-treatment, both feet were swabbed with a 2% iodine in 95% alcohol solution which was permitted to air dry. The pads were then covered with a 50% mixture of starch in castor oil. When sweat was produced, it reacted with the "starch/iodine film" and was visible as a black spot at each pore. Sweating may occur spontaneously in rats or can be induced by an injection of 2% pilocarpine. Photos were taken for future evalution.
A material was considered effective (+) if all six rats exhibited 100~ inhibition of the treated foot. A
material which induced a marked decrease in the number of black dots per treated foot, was rated weakly effective (+). When a material did not differ from the untreated control, it was rated ineffective (-).
Using the above procedure, a series of antihistamines were tested in using the antihistamine enhancers of this invention. The results of these tests are summarized in Table II below:
TABLE II
-20%* 20%* 15%* 95%*
Sodium Q-Glutamic DOWANOL CERAPHYL
Antihistamines (5%) Sulfate AcidPM 368 . .
Antazoline phosphate +
Pyrilamine maleate + +
Tripelennamine hydro-chloride +
Diphenhydramine hydrochloride + +
Doxylamine succinate - +
Chlorpheniramine maleate Pheniramine maleate Phenindamine tartrate + +
.
* Aqueous solutions Although the invention has been described with reference to specific forms thereof, it will be understood that many changes and modifications may be made without departing from the spirit of this invention.
This invention relates to topical antiperspirant compositions that make use of certain antihistamines. More particularly, it concerns compositions of this character that contain an enhancer for the antiperspirant activity of said antihistamines.
It has been suggested in the prior art to use certain antihistamines, alone or in combination with astringent metallic salts, as antiperspirant agents. This is exemplified by two U.S. Patents to Packman et al 4,226,850 and 4,234,566.
In addition, in an article by Goodall published in the J.
Clin. Pharm., Vol. 10, 1970, p. 235-246, it is suggested that certain anticholenergic or cholenergic blocking agents exhibit varying degrees of antiperspirant activity. Among the drugs that Goodall characterizes as anticholenergic drugs, he includes chlorpheniramine maleate, phenindamine tartrate, diphenhydramine HCl and tripelennamine HCl.
A somewhat similar disclosure is to be found in "Advances in Modern Toxicology", Vol. 4, Dermatology and Pharmacology, Chapter 1, pages 2-15, edited by Francis N. Marzuli and Howard I. Maibach, published 1977, John Wiley & Sons, New York.
One thing that is quite clear from this prior art is that the vehicle from which these drugs are applied is important. The level of antiperspirant activity that these drugs exhibit is very much dependent upon the contents of the vehicle in which they are dispensed.
It has now been found that the antiperspirant activity of certain antihistamines may be enhanced by incorporating in a vehicle containing said antihistamine, an enhancer for said antihistamine described in more detail below.
~ V~4 It is accordingly an object of an aspect of the present invention to provide an antiperspirant composition contain-ing certain antihistamines as an active antiperspirant agent and also containing certain agents that enhance the anti-perspirant activity of said antihistamines.
It is an object of an aspect of this invention to provide a process for inhibiting perspiration in a subject that makes use of the antiperspirant composition of the aforesaid object.
Other and more detailed objects of this invention will - be apparent from the following description and claims.
An aspect of this invention is as follows:
A topical antiperspirant composition comprising an active antiperspirant agent consisting essentially of an antihistamine distributed in a vehicle containing an enhancer for the antiperspirant activity of said antihistamine (a) said antihistamine being selected from the group consisting of antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their corresponding pharmaceutically acceptable salts;
(b) said antihistamine enhancer being selected from the group consisting of sodium sulfate, glutamic acid, octyl palmitate and propylene glycol methyl ether;
(c) said antihistamine being present in said vehicle in sufficient concentration to inhibit perspiration; and (d) said enhancer also being present in said vehicle at a concentration sufficient to enhance the antiperspirant effectiveness of said antihistamine.
In the practice of the present invention, it has been found that it is necessary to be quite selective in the antihistamine that is employed. For the purposes of this invention, a composition is an effective antiperspirant composition if it could be demonstrated to be at least weakly effective in the Rat Foot Pad Model described in ~25603~
-2a-more detail below without regard as to whether these results could be corroborated in clinical studies in human antiper-spirant panels. The antihistamines that were found to be effective in accordance with the present invention are antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their pharmaceutically acceptable salts.
The type of salts of the aforesaid antihistamines that are useful for the purposes of this invention can vary. By way of example, the following may be mentioned: phosphates, maleates, hydrochlorides, succinates and tartrates.
The quantity of antihistamine that may be contained in the present compositions may vary somewhat depending on the vehicle utilized and the results that are desired.
However, generally, this will be in the range of from about lS 1% to about 10~ by weight based on the total weight of the ~25~34 composition; the preferred range being from about 3% to about 5% on the same weight basis.
As previously indicated, it is a feature of the present invention to incorporate in the instant antiper-spirant compositions certain enhancers for the antiperspirantactivity of the antihistamines employed. These also are quite selective and include sodium sulfate, glutamic acid (e.g. ~-glutamic acid) octyl palmitate and propylene glycol methyl ether. The quantity of the antihistamine enhancers that will be present in these compositions may also vary somewhat. Usually, this will constitute between about 5% to about 95% by weight based on the total weight of the composition. Best results are obtained when the antiperspirant enhancer utilized falls within the range of from about 5% to about 30% by weight based on the total weight of the composition.
In accordance with the present invention, the anti-histamine and the antihistamine enhancer will be distributed in a suitable vehicle which will generally be a liquid or fluid carrier. This will include solutions, suspensions, lotions, creams, ointments and the like. A variety of carriers may be employed but usually this will be an aqueous based carrier. By way of example, the following carriers may be mentioned: water, propylene glycol, ethanol, ~olatile silicones, ethoxylated ethers, isopropyl myristate and palmitate, etc.
In addition to the components mentioned above, the compositions of this invention may also contain those well known ingredients or adjuvants commonly found in antiperspirant compositions. These include such things as perfumes, coloring agents, stabilizers, buffers, thickeners, emulsifiers, etc.
~2S6034 The compositions of the present invention may be applied to a subject in the conventional manner to inhibit perspiration. Usually, this will involve applying to axillary vault of the subject a quantity of the composition sufficient to inhibit perspiration. This may vary depending upon the results desired, the concentration of the active ingredients and the vehicle employed. Generally, enough of the composition will be applied to dellver to the site from about 10 mgs to about 15 mgs of antihistamine per axilla.
The following Examples are given to further illustrate this invention. It is to be understood, however, that the invention is not limited thereto.
There is given in tabular form in Table I below Examples of the following invention in which the vehicle is primarily water in which the antihistamine and enhancer are dissolved.
--~25~034 TABLE I
~ by Weight based on total wt. of composition Ex Ex Ex Ex Ex ExEx Ex Antihistamine (1) Antazoline phosphate 5 -- -- -- -- -- -- --( 2 ) Pyri lamine maleate -- 5 -- -- -- -- 5 --(3) Tripelennamine hydrochloride -- -- 5 -- -- ~~ ~~ ~~
(4) Diphenhydramine hydrochloride -- -- -- 5 -- -- -- 5 (5) Phenindamine tartrate -- -- -- -- 5 5 -- --Enhancers (6) Sodium sulfate 20 20 20 20 20 -- -- --(7) Q-glutamic acid -- -- -- -- -- 20-- --*
(8) DOWANOL PM -- -- -- -- -- --15 --~ **
(9) CERAPHYL 368 -- -- -- -- -- -- -- 95 Vehicle (10) Water QS 100 100 100 100 100 100 100 --* Propylene glycol methyl ether ** Octyl palmitate As indicated previously, the antiperspirant effectiveness of the compositions of the present invention were evaluated using the Rat Foot Pad Model. This procedure is discussed below.
~,~, 125~34 Rat Foot Pad Model Materials and Methods Female rats were utilized since they sweated more consistently than the male rats. Each material was evaluated in six Sprague Dawley rats (Taconic Farms, weight range 175-250 gm).
Three animals were injected (i.m.) in the right hind limb and three in the left hind limb (biceps femoris area) with 0.02 ml of Innovar Vet. This dose sedated the rats and facilitated placing them into polyethylene harnesses which were then fastened around each animal using binder clips.
The harnessed rats were attached horizontally to supportiny rods by wire hooks. In this manner, they were prevented from walking or licking their feet during the test.
Prior to treatment, the foot pads of both hind feet were swabbed with 70% alcohol to remove cellular debris.
Treatment consisted of immersing the right hind foot into the test material for one minutê. The foot was then allowed to air dry. The left hind foot served as an untreated control.
Observation of Sweat Inhibition/Rating One hour post-treatment, both feet were swabbed with a 2% iodine in 95% alcohol solution which was permitted to air dry. The pads were then covered with a 50% mixture of starch in castor oil. When sweat was produced, it reacted with the "starch/iodine film" and was visible as a black spot at each pore. Sweating may occur spontaneously in rats or can be induced by an injection of 2% pilocarpine. Photos were taken for future evalution.
A material was considered effective (+) if all six rats exhibited 100~ inhibition of the treated foot. A
material which induced a marked decrease in the number of black dots per treated foot, was rated weakly effective (+). When a material did not differ from the untreated control, it was rated ineffective (-).
Using the above procedure, a series of antihistamines were tested in using the antihistamine enhancers of this invention. The results of these tests are summarized in Table II below:
TABLE II
-20%* 20%* 15%* 95%*
Sodium Q-Glutamic DOWANOL CERAPHYL
Antihistamines (5%) Sulfate AcidPM 368 . .
Antazoline phosphate +
Pyrilamine maleate + +
Tripelennamine hydro-chloride +
Diphenhydramine hydrochloride + +
Doxylamine succinate - +
Chlorpheniramine maleate Pheniramine maleate Phenindamine tartrate + +
.
* Aqueous solutions Although the invention has been described with reference to specific forms thereof, it will be understood that many changes and modifications may be made without departing from the spirit of this invention.
Claims (24)
1. A topical antiperspirant composition comprising an active antiperspirant agent consisting essentially of an antihistamine distributed in a vehicle containing an enhancer for the antiperspirant activity of said antihistamine (a) said antihistamine being selected from the group consisting of antazoline, pyrilamine, tripelennamine, diphenhydramine, phenindamine and their corresponding pharmaceutically acceptable salts;
(b) said antihistamine enhancer being selected from the group consisting of sodium sulfate, glutamic acid, octyl palmitate and propylene glycol methyl ether;
(c) said antihistamine being present in said vehicle in sufficient concentration to inhibit perspiration; and (d) said enhancer also being present in said vehicle at a concentration sufficient to enhance the antiperspirant effectiveness of said antihistamine.
(b) said antihistamine enhancer being selected from the group consisting of sodium sulfate, glutamic acid, octyl palmitate and propylene glycol methyl ether;
(c) said antihistamine being present in said vehicle in sufficient concentration to inhibit perspiration; and (d) said enhancer also being present in said vehicle at a concentration sufficient to enhance the antiperspirant effectiveness of said antihistamine.
2. A composition according to Claim 1 in which said antihistamine is present in said composition in the range of from about 1% to about 10% by weight based on the total weight of said composition.
3. A composition according to Claim 1 in which said antihistamine enhancer is present in said composition in the range of from about 5% to about 95% by weight based on the total weight of said composition.
4. A composition according to Claim 1 in which said antihistamine is present in said composition in the range of from about 1% to about 10% by weight based on the total weight of said composition and said antihistamine enhancer is present in said composition in the range of from about 5% to about 95% based on the total weight of said composition.
5. A composition according to Claim 1 in which said antihistamine is present in said composition in the range of from about 3% to about 5% by weight based on the total weight of said composition.
6. A composition according to Claim 1 in which said antihistamine enhancer is present in said composition in the range of from about 5% to about 30% by weight based on the total weight of said composition.
7. A composition according to Claim 1 in which said antihistamine is present in said composition in the range of from about 3% to about 5% by weight based on the total weight of said composition and said antihistamine enhancer is present in said composition in the range of from about 5% to about 30% by weight based on the total weight of said composition.
8. A composition according to Claim 7 in which said antihistamine enhancer is sodium sulfate.
9. A composition according to Claim 8 in which said antihistamine is pyrilamine maleate.
10. A composition according to Claim 8 in which said antihistamine is tripelennamine hydrochloride.
11. A composition according to Claim 8 in which said antihistamine is phenindamine tartrate.
12. A composition according to Claim 7 in which said antihistamine enhancer is ?-glutamic acid.
13. A composition according to Claim 12 in which said antihistamine is phenindamine tartrate.
14. A composition according to Claim 7 in which said antihistamine enhancer is propylene glycol methyl ether.
15. A composition according to Claim 14 in which said antihistamine is pyrilamine maleate.
16. A composition according to Claim 7 in which said antihistamine enhancer is octyl palmitate.
17. A composition according to Claim 16 in which said antihistamine is diphenhydramine hydrochloride.
18. An antiperspirant method comprising applying the antiperspirant composition of Claim 1 to the skin of a living subject.
19. An antiperspirant method comprising applying the antiperspirant composition of Claims 2, 3, or 4 to the skin of a living subject.
20. An antiperspirant method comprising applying the antiperspirant composition of Claims 5, 6, or 7 to the skin of a living subject.
21. An antiperspirant method comprising applying the antiperspirant composition of Claims 8, 9, or 10 to the skin of a living subject.
22. An antiperspirant method comprising applying the antiperspirant composition of Claims 11, 12, or 13 to the skin of a living subject.
23. An antiperspirant method comprising applying the antiperspirant composition of Claims 14, 15, or 16 to the skin of a living subject.
24. An antiperspirant method comprising applying the antiperspirant composition of Claim 17 to the skin of a living subject.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50693083A | 1983-06-22 | 1983-06-22 | |
| US506,930 | 1983-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1256034A true CA1256034A (en) | 1989-06-20 |
Family
ID=24016540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000457159A Expired CA1256034A (en) | 1983-06-22 | 1984-06-21 | Antiperspirant compositions containing certain antihistamines and certain antihistamine enhancers |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1256034A (en) |
-
1984
- 1984-06-21 CA CA000457159A patent/CA1256034A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2812690B2 (en) | Photoprotective composition containing tocopherol sorbate | |
| CA1146070A (en) | Topical triethylenetetramine-containing pharmaceutical compositions and methods of use | |
| JP2897832B2 (en) | Light protection composition containing chelating agent | |
| US4518789A (en) | Phenyl alpha-acyloxyacetamide derivatives and their therapeutic use | |
| JPH01265015A (en) | Light protective composition containing sorbic acid, tocopherol and anti-inflammatory drug | |
| US4264581A (en) | Sunscreen composition | |
| CA2070685C (en) | Method for treating painful, inflammatory or allergic disorders | |
| US4234566A (en) | Antihistamine and methods for use thereof | |
| US4039664A (en) | Topical griseofulvin composition and method | |
| US5098717A (en) | Method of treatment for pruritus | |
| JPH0347252B2 (en) | ||
| GB2181051A (en) | Anti-acne compositions | |
| EP0275719A2 (en) | Ultraviolet absorbing compounds and formulations including same | |
| KR900014406A (en) | Cefem compound and preparation method thereof | |
| US4226850A (en) | Methods for controlling perspiration | |
| US4762704A (en) | Antiperspirant compositions, containing certain antihistamines and certain antihistamine enhancers | |
| CA1256034A (en) | Antiperspirant compositions containing certain antihistamines and certain antihistamine enhancers | |
| US5208015A (en) | Topical anti-fungal agents having anti-inflammatory activity | |
| JPH09291016A (en) | Hair cosmetic material | |
| US3984535A (en) | Scalp deodorant composition | |
| EP0419164A1 (en) | Hair conditioning composition | |
| US4654339A (en) | 3-amino-tetrahydro-1,3-thiazine-2,4-diones, utilization thereof and skin treating compositions containing said compounds | |
| US5028418A (en) | Antiperspirant process and imdazole containing compositions utilizable therein | |
| EP1150671B1 (en) | Use of pyrethroid compounds to promote hair growth | |
| US5151269A (en) | Topical anesthetic composition comprising a capped polyoxyalkylene alcohol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |